Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2019

Open Access 01-02-2019 | Original Article

Bactericidal/Permeability-Increasing Fold-Containing Family B Member 4 May Be Associated with NSAID-Induced Enteropathy

Authors: Shunji Fujimori, Koya Fukunaga, Atsushi Takahashi, Taisei Mushiroda, Michiaki Kubo, Ryuzo Hanada, Mari Hayashida, Toshiyuki Sakurai, Katsuhiko Iwakiri, Choitsu Sakamoto

Published in: Digestive Diseases and Sciences | Issue 2/2019

Login to get access

Abstract

Background

There is considerable individual variability in nonsteroidal anti-inflammatory drug (NSAID)-induced enteropathy.

Aim

To identify the SNP that is most significantly involved with NSAID-induced enteropathy.

Methods

One hundred fifty human subjects who were known to have a certain degree of loxoprofen- or celecoxib-induced small-intestinal damage from a previous study were enrolled. The subjects were divided into groups based on treatments and also on the increased number of small intestinal mucosal breaks. The candidate SNP was selected by an initial analysis of GWAS among the groups in various combinations. After the initial analysis, the gene including the specified SNP was analyzed in detail using GWAS and genotype imputation.

Results

After analysis, 70 subjects receiving the loxoprofen treatment and 69 subjects receiving celecoxib treatment were determined to be eligible for the analysis. The minimum p value in GWAS was detected in the analysis of 16 cases with an increase of five or more mucosal breaks and 123 controls with zero to four mucosal breaks. In the GWAS, five SNPs in the bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) gene showed the lowest p value (p = 2.69 × 10−7 with an odds ratio of 40.9). Of the five SNPs, four were nonsynonymous SNPs (rs2070325: V268I, rs2889732: T320N, rs11699009: F527L, rs11696307: T533I, and rs11696310: intronic). Furthermore, 23 SNPs in BPIFB4 detected by genotype imputation based on the GWAS data also showed suggestive associations (p < 1 × 10−6).

Conclusion

The results indicate that SNPs in BPIFB4 were associated with NSAID-induced small intestinal mucosal injury (UMIN: 000007936).
Appendix
Available only for authorised users
Literature
1.
go back to reference Graham DY, Opekun AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59.CrossRef Graham DY, Opekun AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59.CrossRef
2.
go back to reference Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172–1178.CrossRefPubMed Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172–1178.CrossRefPubMed
3.
go back to reference Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133–141.CrossRefPubMed Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133–141.CrossRefPubMed
4.
go back to reference Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007;25:1211–1222.CrossRefPubMed Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007;25:1211–1222.CrossRefPubMed
5.
go back to reference Fujimori S, Takahashi Y, Seo T, et al. Prevention of traditional NSAID-induced small intestinal injury: recent preliminary studies using capsule endoscopy. Digestion. 2010;82:167–172.CrossRefPubMed Fujimori S, Takahashi Y, Seo T, et al. Prevention of traditional NSAID-induced small intestinal injury: recent preliminary studies using capsule endoscopy. Digestion. 2010;82:167–172.CrossRefPubMed
6.
go back to reference Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69:1339–1346.CrossRefPubMed Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69:1339–1346.CrossRefPubMed
7.
go back to reference Fujimori S, Takahashi Y, Gudis K, et al. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol. 2011;46:57–64.CrossRefPubMed Fujimori S, Takahashi Y, Gudis K, et al. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol. 2011;46:57–64.CrossRefPubMed
8.
go back to reference Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol. 2005;3:564–573.CrossRefPubMed Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol. 2005;3:564–573.CrossRefPubMed
9.
go back to reference Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133:465–471.CrossRefPubMed Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133:465–471.CrossRefPubMed
10.
go back to reference Fujimori S, Hanada R, Hayashida M, et al. Celecoxib monotherapy maintained small intestinal mucosa better compared with loxoprofen plus lansoprazole treatment: a double-blind, randomized, controlled trial. J Clin Gastroenterol. 2016;50:218–226.CrossRefPubMed Fujimori S, Hanada R, Hayashida M, et al. Celecoxib monotherapy maintained small intestinal mucosa better compared with loxoprofen plus lansoprazole treatment: a double-blind, randomized, controlled trial. J Clin Gastroenterol. 2016;50:218–226.CrossRefPubMed
12.
go back to reference van Leeuwen EM, Kanterakis A, Deelen P, et al. Population-specific genotype imputations using minimac or IMPUTE2. Nat Protoc. 2015;10:1285–1296.CrossRefPubMed van Leeuwen EM, Kanterakis A, Deelen P, et al. Population-specific genotype imputations using minimac or IMPUTE2. Nat Protoc. 2015;10:1285–1296.CrossRefPubMed
13.
14.
15.
16.
go back to reference Canny G, Levy O. Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites. Trends Immunol. 2008;29:541–547.CrossRefPubMed Canny G, Levy O. Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites. Trends Immunol. 2008;29:541–547.CrossRefPubMed
17.
go back to reference Bingle CD, Bingle L, Craven CJ. Distant cousins: genomic and sequence diversity within the BPI fold-containing (BPIF)/PLUNC protein family. Biochem Soc Trans. 2011;39:961–965.CrossRefPubMed Bingle CD, Bingle L, Craven CJ. Distant cousins: genomic and sequence diversity within the BPI fold-containing (BPIF)/PLUNC protein family. Biochem Soc Trans. 2011;39:961–965.CrossRefPubMed
18.
go back to reference Bjarnason I, Williams P, So A, Zanelli G, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;2:1171–1174.CrossRefPubMed Bjarnason I, Williams P, So A, Zanelli G, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;2:1171–1174.CrossRefPubMed
19.
go back to reference Whittle BJ. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol. 2004;500:427–439.CrossRefPubMed Whittle BJ. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol. 2004;500:427–439.CrossRefPubMed
20.
go back to reference Bjarnason I, Hayllar J, Smethurst P, et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut. 1992;33:1204–1208.CrossRefPubMedPubMedCentral Bjarnason I, Hayllar J, Smethurst P, et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut. 1992;33:1204–1208.CrossRefPubMedPubMedCentral
21.
go back to reference Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1322. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1322.
22.
go back to reference Villa F, Carrizzo A, Spinelli CC, et al. Genetic analysis reveals a longevity-associated protein modulating endothelial function and angiogenesis. Circ Res. 2015;117:333–345.CrossRefPubMedPubMedCentral Villa F, Carrizzo A, Spinelli CC, et al. Genetic analysis reveals a longevity-associated protein modulating endothelial function and angiogenesis. Circ Res. 2015;117:333–345.CrossRefPubMedPubMedCentral
23.
go back to reference Spinetti G, Sangalli E, Specchia C, et al. The expression of the BPIFB4 and CXCR4 associates with sustained health in long-living individuals from Cilento-Italy. Aging. 2017;9:370–380.CrossRefPubMedPubMedCentral Spinetti G, Sangalli E, Specchia C, et al. The expression of the BPIFB4 and CXCR4 associates with sustained health in long-living individuals from Cilento-Italy. Aging. 2017;9:370–380.CrossRefPubMedPubMedCentral
24.
go back to reference Vecchione C, Villa F, Carrizzo A, et al. A rare genetic variant of BPIFB4 predisposes to high blood pressure via impairment of nitric oxide signaling. Sci Rep. 2017;7:9706.CrossRefPubMedPubMedCentral Vecchione C, Villa F, Carrizzo A, et al. A rare genetic variant of BPIFB4 predisposes to high blood pressure via impairment of nitric oxide signaling. Sci Rep. 2017;7:9706.CrossRefPubMedPubMedCentral
25.
go back to reference Spinelli CC, Carrizzo A, Ferrario A, Villa F, et al. LAV-BPIFB4 isoform modulates eNOS signalling through Ca2+/PKC-alpha-dependent mechanism. Cardiovasc Res. 2017;113:795–804.CrossRefPubMedPubMedCentral Spinelli CC, Carrizzo A, Ferrario A, Villa F, et al. LAV-BPIFB4 isoform modulates eNOS signalling through Ca2+/PKC-alpha-dependent mechanism. Cardiovasc Res. 2017;113:795–804.CrossRefPubMedPubMedCentral
26.
go back to reference Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of damage to the gastrointestinal tract from non-steroidal anti-inflammatory drugs. Gastroenterology. 2018;154:500–514.CrossRefPubMed Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of damage to the gastrointestinal tract from non-steroidal anti-inflammatory drugs. Gastroenterology. 2018;154:500–514.CrossRefPubMed
Metadata
Title
Bactericidal/Permeability-Increasing Fold-Containing Family B Member 4 May Be Associated with NSAID-Induced Enteropathy
Authors
Shunji Fujimori
Koya Fukunaga
Atsushi Takahashi
Taisei Mushiroda
Michiaki Kubo
Ryuzo Hanada
Mari Hayashida
Toshiyuki Sakurai
Katsuhiko Iwakiri
Choitsu Sakamoto
Publication date
01-02-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5349-0

Other articles of this Issue 2/2019

Digestive Diseases and Sciences 2/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.